PureTech Founded Entity Vor Biopharma Announces VOR33 Granted US FDA Fast Track Designation for Acute Myeloid Leukemia

PureTech Health plc announced that its Founded Entity, Vor Biopharma announced that the US FDA has granted Fast Track designation to VOR33, Vor’s lead engineered hematopoietic stem cell therapeutic candidate for the treatment of acute myeloid leukemia.